Anastasiya A. Filimonova

Anastasiya A. Filimonova

Auto-generated profile, based on publicly available information

Anastasiya A. Filimonova

ГБУ Рязанской области "Областной клинический кардиологический диспансер

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
NFN. V. Fedorova
N. V. Fedorova
DSD. Yu. Sedykh
D. Yu. Sedykh
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
OKO. N. Khryachkova
O. N. Khryachkova
ДСД. Ю. Седых
Д. Ю. Седых
Aim. To assess the efficacy and safety of PCSK9 inhibitor alirocumab as part of a combination lipid-lowering therapy in patients with acute coronary syndrome (ACS).Material and methods. This prospective, open-label, single-center activetreatment study included 13 patients hospitalized due to ACS. The main inclusion criterion was nonachievement of target low-density lipoprotein cholesterol (LDL-C) values (<1,4 mmol/L) with high-intensity statin therapy prior to ACS. During the first 30 days after ACS, all patients received therapy with atorvastatin 40-80 mg/day or rosuvastatin 20-40 mg/day in combination with alirocumab 150 mg/ml (Praluent) administered by subcutaneous injection. Lipid and biochemical profiles were monitored. The first injection of the PCSK9 inhibitor was performed on days 3-5 of hospitalization, the second — after 2 weeks.Results. On admission, the median LDL-C was 4,3 [3,5;5,3] mmol/L. A day after administration, there was a decrease in LDL-C by 41,9% (median 2,5 [1,8;3,2] mmol/L; p=0,001) without a negative effect on high-density lipoproteins (HDL-C) (median 1,2 [0,8;1,4] mmol/L; p=0,270). Before the next injection, LDL-C decreased by another 8% (median 2,3 [1,1;4,1] mmol/L). A day after the second injection, a decrease in LDL-C from the baseline values was 69,8% (median 1,3 [0,7;1,5] mmol/L; p=0,010). Strengthening lipid-lowering therapy with a PCSK9 inhibitor within 30 days after ACS did not lead to clinical and biochemical deterioration.Conclusion. The use of subcutaneous 150-mg injections of alirocumab 2 times a week 30 days after ACS in patients who did not reach target LDL-C values with statin therapy, leads to a 69% decrease in LDL-C from baseline values and is safe.

30 September 2022 in Nauka Molodykh (Eruditio Juvenium)
Verified
Journal Article
Closed access
AFA. A. Filimonova
A. A. Filimonova
RURyazan State Medical University
Ryazan State Medical University
YSYe. M. Shurpo
Ye. M. Shurpo
Stanislav KotlyarovStanislav Kotlyarov
Stanislav Kotlyarov
ABA. A. Bulgakov
A. A. Bulgakov
CHCity Clinical Emergency Hospital
City Clinical Emergency Hospital
INTRODUCTION: The pandemic of a new coronavirus infection, COVID-19, has placeda heavy burden on the health care system. Nowadays, the clinical and epidemic features of the disease are the subject of debate and have not been adequately studied. Studies on the effect of coronavirus on the cardiovascular system deserve special attention. They are of significant interest because myocardial damage is the second most frequent cause of death in COVID-19. The damaging effect of the virus on the cardiovascular system is multifactorial and is realized both through the direct effect of the virus on its elements and indirectly. In the long term, COVID-19 patients with myocardial lesions retain an increased risk of cardiovascular events and require monitoring by a cardiologist. CONCLUSION: Development of preventive measures, improvement of diagnosis and treatment tactics of cardiovascular diseases in COVID-19 is the main task of further long-term studies. The present review aims to discuss the pathogenetic mechanisms of the development of the main forms of acute myocardial damage in COVID-19, as well as to analyze their clinical significance and approaches to diagnosis.

16 July 2023 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
OUOleg M. Uryasyev
Oleg M. Uryasyev
ASAleksandra V. Solov’yEva
Aleksandra V. Solov’yEva
ACAleksey V. Cheskidov
Aleksey V. Cheskidov
AFAnastasiya A. Filimonova
Anastasiya A. Filimonova
ENEkaterina А. Nikiforova
Ekaterina А. Nikiforova
INTRODUCTION: Obesity is one of the leading risk factors for the development of cardiovascular diseases. At present, of the greatest scientific interest are local deposits of adipose tissue as a possible morphological substrate for the development of this group of diseases. Along with the traditional risk factors, one more risk factor for a poor prognosis of cardiovascular disease can be a change in the thickness of the epicardial fat (EF) and of the interatrial septum (IAS) in case of its lipomatosis. AIM: To study the significance of EF and of IAS thickness as markers of cardiovascular risk in coronary heart disease. MATERIALS AND METHODS: The study involved 116 individuals with coronary heart disease (55 men (47%) and 61 women (53%), mean age 68 [61; 72] years). Thickness of EF and IAS was evaluated by the method of echocardiography. The frequency of poor outcomes was evaluated using KaplanMeier method, ROC-curve analysis. The differences were considered statistically significant at p 0.05. RESULTS: In the group of patients with unstable angina, the threshold value of IAS thickness was 0.7 cm (p 0.001), and of EF thickness 0.8 cm (2 = 10.89, p = 0.001), in the group of patients with myocardial infarction 0.7 cm (p 0.001) and 0.8 cm (p 0.001), respectively. In the group of patient with unstable angina, IAS thickness 0.7 cm (2 = 10.3, p = 0.0013) and EF thickness 0.8 cm (2 = 10.89, p = 0.001) demonstrate a poor prognosis in comparison with the parameters below the threshold values. In the group of patients with myocardial infarction, IAS thickness 0.7 cm (2 = 8.4, p = 0.005) and EF 0.8 cm (2 = 9.66, p = 0.0019) demonstrate poor prognosis in comparison with the parameters below the threshold values. CONCLUSION: In unstable angina and myocardial infarction, the value of IAS thickness 0.7 cm (p = 0.0013 and p = 0.005, respectively) and of EF thickness 0.8 cm (p = 0.001 and p = 0.0019, respectively) present a poor prognosis compared to lower values. It is recommended that EF and IAS thickness be determined in echocardiography as an additional marker for a poor prognosis in coronary heart disease.

22 February 2026 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AAA. V. Andreeva
A. V. Andreeva
SYS. S. Yakushin
S. S. Yakushin
AFA. A. Filimonova
A. A. Filimonova
Aim . To study the effect of rehabilitation using intermittent hypoxia-hyperoxia training (IHHT) on anxiety and depression, quality of life (QOL), and exercise tolerance in elderly patients with myocardial infarction (MI) and heart failure (HF). Material and methods. This single-center, prospective, randomized, controlled, parallel-group study included 102 elderly patients with MI and HF. Patients were randomized into two groups: the experimental group (n=51) received standard rehabilitation combined with IHHT using the ReOxy device; the control group (n=51) received standard rehabilitation alone. All patients were assessed for anxiety and depression using the Hospital Anxiety and Depression Scale (HADS), quality of life using the EuroQol-5D questionnaire, and 6-minute walk test distance. Results . The groups were comparable in clinical and demographic characteristics (p>0,05). In the experimental group, compared with the standard rehabilitation group, there was a more pronounced decrease in the HADS score (2,0 (0,0; 7,0) vs 1,0 (0,0; 4,0), p=0,040) and an improvement in QOL according to the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) visual analogue scale (20,0% (0,0; 30,0) vs 15,0% (-25,0; 30,0), p=0,044). This was accompanied by a greater increase in distance during the 6-minute walk test (up to 51,0 (33,0; 86,0) m in the experimental group vs 30,0 (22,5; 56,0) m, p=0,001). Conclusion . Adding IHHT to a standard rehabilitation program for patients with MI and HF reduces anxiety, improves QOL, and improves exercise tolerance.

1 January 2022 in Вестник Алматинского университета энергетики и связи
Verified
Journal Article
Closed access
TGTatyana Golubeva
Tatyana Golubeva
VTV.A. Tailakov
V.A. Tailakov
FYF.B. Yakubov
F.B. Yakubov
AFA.A. Filimonova
A.A. Filimonova